Corbus Pharmaceuticals Holdings Inc
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | ||
| Date: March 12, 2024 | By: | /s/ YUVAL COHEN |
|---|---|---|
| Name: | Yuval Cohen | |
| Title: | Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ YUVAL COHEN | Chief Executive Officer and Director(Principal Executive Officer) | March 12, 2024 |
| Yuval Cohen | ||
| /s/ SEAN MORAN | Chief Financial Officer(Principal Financial and Accounting Officer) | March 12, 2024 |
| Sean Moran | ||
| /s/ ALAN HOLMER | Director | March 12, 2024 |
| Alan Holmer | ||
| /s/ ANNE ALTMEYER | Director | March 12, 2024 |
| Anne Altmeyer | ||
| /s/ AVERY CATLIN | Director | March 12, 2024 |
| Avery Catlin | ||
| /s/ RACHELLE JACQUES | Director | March 12, 2024 |
| Rachelle Jacques | ||
| /s/ JOHN JENKINS | Director | March 12, 2024 |
| John Jenkins | ||
| /s/ PETER SALZMANN | Director | March 12, 2024 |
| Peter Salzmann | ||
| /s/ YONG BEN | Director | March 12, 2024 |
| Yong Ben | ||
INDEX TO FINANCIAL STATEMENTS
| Page Number | |
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Corbus Pharmaceuticals Holdings, Inc. Financial Statements-December 31, 2023: | |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2023 and 2022 | F-6 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.